Glucotrack Announces Publication Of Peer Reviewed Scientific Article In The Journal Of Diabetes Research On Long-Term Accuracy And Stability Of Fully Implantable CBGM System In In-Vivo Ovine Model

Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the publication of a peer reviewed scientific article in The Journal of Diabetes Research on the long-term accuracy and stability of the Company's fully implantable continuous blood glucose monitoring (CBGM) system in an in-vivo ovine model.

The study, titled "In Vivo Evaluation of a Novel Long-Term Intravascular Implantable Continuous Blood Glucose Monitor in an Ovine Model: A Glucotrack™ Inc. Investigation," (Tapsak, M. A. et al.), evaluated the in-vivo performance of the CBGM in an ovine model over periods of up to 240 days. The study examined 34 devices that were successfully implanted into 17 adult sheep. Results demonstrated a weighted average Mean Absolute Relative Difference (MARD) of 6.8% across 79 intravenous glucose tolerance tests conducted during the study period, demonstrating excellent accuracy. The devices maintained consistent glucose sensing performance, with no device-related adverse safety events observed, over the up to 240-day study period.